Streptozocin

Summary

Streptozocin (CHEMBL1977579) is an approved small molecule (ATC L01AD04); indicated across 10 conditions including neoplasm and carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01AD04
• Indications: 10 conditions
• Clinical trials: 7
• Chemistry: 265.22 Da · C8H15N3O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1977579
Name	Streptozocin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23615975
ATC	L01AD04
Molecular formula	C8H15N3O7
Molecular weight	265.22
InChIKey	AGRCPNMCOXLKFO-BDVNFPICSA-N

SMILES: CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O

IUPAC name: 1-methyl-1-nitroso-3-[(2R,3R,4S,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]urea

Also known as: Estreptozocina, NSC-37917, NSC-85998, Streptozocin, Streptozocine, Streptozotocin, Stz, U-9889, Zanosar, streptozotocin, STREPTOZOCIN, streptozocin

Patent coverage: 24 distinct patent families (74 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
carcinoma	3	MONDO:0004993	EFO:0000313
neuroendocrine neoplasm	3	MONDO:0019496	EFO:1001901
glioblastoma	2	MONDO:0018177	EFO:0000519
anaplastic astrocytoma	2	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	2	MONDO:0016696	EFO:0002501
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
glioma	2	MONDO:0021042	MONDO:0003268
brain neoplasm	2	MONDO:0021211	EFO:0003833
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00094497	PHASE3	COMPLETED	Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
NCT03351296	PHASE2	ACTIVE_NOT_RECRUITING	Two Chemotherapy Regimens Plus or Minus Bevacizumab
NCT00004688	PHASE2	COMPLETED	Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
NCT00448136	PHASE2	COMPLETED	A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
NCT00602082	PHASE2	COMPLETED	Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
NCT00609765	PHASE2	TERMINATED	Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
NCT00003543	PHASE1	COMPLETED	Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).